!!
Efficacy and tolerability of #erenumab in patients with episodic #migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
Between March 20, 2017, and Oct 27, 2017, 246 participants were randomly assigned, 121 to the erenumab group and 125 to the placebo group. 95 of 246 (39%) participants had previously unsuccessfully tried two preventive drugs, 93 (38%) had tried three, and 56 (23%) had tried four. At week 12, 36 (30%) patients in the erenumab had a 50% or greater reduction from baseline in the mean number of monthly migraine days, compared with 17 (14%) in the placebo group (odds ratio 2·7 95% CI 1·4–5·2; p=0·002). The tolerability and safety profiles of erenumab and placebo were similar. The most frequent treatment-emergent adverse event was injection site pain, which occurred in seven (6%) participants in both groups.
Interpretation
Compared with placebo, erenumab was efficacious in patients with episodic migraine who previously did not respond to or tolerate between two and four previous migraine preventive treatments. Erenumab might be an option for patients with difficult-to-treat migraine who have high unmet needs and few treatment options
Efficacy and tolerability of #erenumab in patients with episodic #migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
Between March 20, 2017, and Oct 27, 2017, 246 participants were randomly assigned, 121 to the erenumab group and 125 to the placebo group. 95 of 246 (39%) participants had previously unsuccessfully tried two preventive drugs, 93 (38%) had tried three, and 56 (23%) had tried four. At week 12, 36 (30%) patients in the erenumab had a 50% or greater reduction from baseline in the mean number of monthly migraine days, compared with 17 (14%) in the placebo group (odds ratio 2·7 95% CI 1·4–5·2; p=0·002). The tolerability and safety profiles of erenumab and placebo were similar. The most frequent treatment-emergent adverse event was injection site pain, which occurred in seven (6%) participants in both groups.
Interpretation
Compared with placebo, erenumab was efficacious in patients with episodic migraine who previously did not respond to or tolerate between two and four previous migraine preventive treatments. Erenumab might be an option for patients with difficult-to-treat migraine who have high unmet needs and few treatment options
Early Use of #Erenumab vs Nonspecific Oral #Migraine PreventivesThe APPRAISE Randomized Clinical Trial
https://2medical.news/2024/04/03/early-use-of-erenumab-vs-nonspecific-oral-migraine-preventivesthe-appraise-randomized-clinical-trial/
https://2medical.news/2024/04/03/early-use-of-erenumab-vs-nonspecific-oral-migraine-preventivesthe-appraise-randomized-clinical-trial/
2Medical.News
Early Use of #Erenumab vs Nonspecific Oral #Migraine PreventivesThe APPRAISE Randomized Clinical Trial
Importance Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease…